Corp 1000

Sanofi upped to hold at Deutsche Bank as Zantac fears make a sell ‘egregious’

Sanofi was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22. “We think the Zantac knee-jerk is starting to look somewhat overdone. This doesn’t make for an obvious buying opportunity in our view, but maintaining a sell at these levels feels egregious,” said analyst Emmanuel Papadakis. Of companies also impacted by Zantac worries, GSK climbed 2.5% in early London action while Haleon slipped a further 0.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Previous post Wave of Chinese companies including PetroChina and Sinopec say they will de-list from NYSE
Next post How To Prevent Your Real Estate Contractor From Holding You Hostage